Lupus Trial Misses Endpoints
Alumis Shares Slide After Lupus Trial Misses Endpoints Despite Japan Licensing Deal
Anonymous
Key Points
1
In its Japan collaboration, Alumis will receive tiered royalties on ESK-001's aggregate net sales in Japan, ranging from low double-digits into the twenties.
2
The Phase 2b LUMUS study in systemic lupus erythematosus did not meet the primary endpoint (BICLA) or key secondary endpoints (CLASI-50, SRI-4, LLDAS) in the overall population, though a prespecified interferon-signature high subgroup showed responses.
3
The LUMUS trial enrolled 408 adults with moderate-to-severe SLE over 48 weeks, a detail that frames the topline results and subsequent development discussions.
4
Alumis shares slid more than 55% in premarket trading following the topline results, underscoring market sensitivity to mid-stage lupus data and the strategic pivot ahead.
5
Beyond SLE, Alumis indicated it is evaluating envudeucitinib for other interferon-driven conditions, including cutaneous lupus and Sjögren’s disease, expanding the potential addressable indications.
Alumis reported that its Phase 2b LUMUS trial in systemic lupus erythematosus failed to meet primary and key secondary endpoints in the overall patient group, sending shares down more than 55% in premarket trading. However, a smaller subset of patients with high interferon gene signatures showed favorable responses, offering a potential path forward as the company weighs next steps with regulators.
Separately, Alumis struck a Japan partnership with Kaken Pharmaceutical for its TYK2 inhibitor ESK-001, securing a $40 million upfront payment and up to $140 million in milestone payments, plus tiered royalties ranging from low double-digits to the twenties on Japanese net sales.
Lupus Trial Stumbles but Interferon Subgroup Shows Promise
The 48-week LUMUS trial enrolled 408 adults with moderate-to-severe systemic lupus erythematosus across multiple sites. The study missed its primary endpoint — BICLA, which measures clinical response — and failed key secondary endpoints including CLASI-50, SRI-4, and LLDAS. But a prespecified subgroup with high interferon gene signatures showed meaningful responses, suggesting envudeucitinib may work better in interferon-driven disease.
Alumis confirmed the drug engaged its target (the interferon pathway) in a dose-dependent manner, with maximum suppression at 40 mg twice daily. The treatment was generally well tolerated, and the company now plans to discuss Phase 3 strategy options with regulators to potentially refocus on interferon-high patients rather than the broader SLE population.
Stock Tanks 55% as Investors Weigh Lupus Setback
Market reaction was swift and severe. Alumis shares plummeted more than 55% in premarket trading immediately after the missed endpoints announcement. The sharp decline reflects investor concerns about the drug's commercial viability and the time and cost required to pivot toward a narrower interferon-high patient population for Phase 3 testing.
Japan Deal Provides Near-Term Cash and Revenue Runway
The Kaken partnership offers Alumis meaningful financial breathing room. Under the agreement, Alumis receives $40 million upfront, near-term milestone payments, and potential total milestone value up to $140 million across development and approval stages. Kaken also gains an option to expand ESK-001 into rheumatology and gastrointestinal diseases, diversifying the program's reach.
Tiered royalties on Japanese net sales will range from low double-digits to the twenties, depending on sales thresholds. This deal insulates Alumis from near-term funding pressures while it regroups on the lupus program and advances other pipeline candidates.
Expanding Into Other Interferon-Driven Conditions
The LUMUS failure may force a strategic reset, but Alumis is exploring envudeucitinib for other interferon-driven diseases beyond SLE, including cutaneous lupus and Sjögren's disease. These indications could inherit the interferon-high subgroup insights from LUMUS and allow the company to capitalize on target engagement data without starting from scratch.
The company remains on track to file a U.S. new drug application for envudeucitinib in moderate-to-severe plaque psoriasis in late 2026. Alumis's broader TYK2 pipeline also includes A-005 for neuroinflammatory diseases and other preclinical programs, providing multiple shots on goal across immunology.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
31
Reach
42
Topics
A
AnonymousAuthor
